Topic: CUREVAC
20 results were found.
CureVac sells COVID-19, flu vaccines to GSK amid restructuring - July 5, 2024
CureVac files patent infringement lawsuit in Germany against BioNTech - July 6, 2022
Germany agrees deal with CureVac, GSK for mRNA vaccines until 2029 - April 12, 2022
CureVac Q3 revenues €29.3 million - November 19, 2021
Bayer, CureVac terminate COVID-19 shot production partnership - October 15, 2021
EMA ends rolling review of CVnCoV COVID-19 vaccine following withdrawal by CureVac AG - October 13, 2021
CureVac Q2 revenue €22.4 million - August 16, 2021
Curevac reports 47% vaccine efficacy rate, share cut in half - June 17, 2021
Moon asks Germany's CureVac to consider South Korea as regional vaccine production hub - June 15, 2021
CureVac seeks COVID-19 shot approval in Switzerland - April 22, 2021
CureVac Swiss initiates rolling submission process COVID-19 vaccine candidate CVnCoV with Swissmedic - April 19, 2021
GSK and CureVac to develop next generation mRNA COVID-19 vaccines - February 3, 2021
CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV - January 7, 2021
EU to authorise CureVac vaccine - November 16, 2020
Germany grants BioNTech, CureVac $745 million to speed up coronavirus vaccine work - September 16, 2020
EU concludes exploratory talks with CureVac to buy potential coronavirus vaccine - August 21, 2020
Glaxo to invest in Germany's CureVac as partner to develop vaccines - July 20, 2020
German vaccine developer CureVac to receive 75 million euros EU loan - July 7, 2020
Germany to buy 300 million euro stake in vaccine developer CureVac - June 16, 2020
CureVac appoints Pierre Kemula as chief financial officer - October 12, 2016